Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTX NASDAQ:CRMD NASDAQ:DRUG NASDAQ:EQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$14.76+8.0%$15.68$4.46▼$24.27$718.57M0.831.39 million shs1.12 million shsCRMDCorMedix$8.74-2.5%$7.81$6.13▼$17.43$702.93M1.461.30 million shs968,765 shsDRUGBright Minds Biosciences$60.95-1.0%$81.58$23.17▼$123.75$599.21M-5.53397,187 shs658,916 shsEQEquillium$2.81$2.27$0.27▼$3.45$177.67M1.771.14 million shs441,284 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+4.35%+0.44%-31.44%-13.48%+190.23%CRMDCorMedix+2.17%+4.92%+19.31%+38.91%-38.59%DRUGBright Minds Biosciences+0.02%-17.87%-27.27%-14.49%+121.87%EQEquillium+6.03%-10.69%+24.71%+14.62%+633.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$14.76+8.0%$15.68$4.46▼$24.27$718.57M0.831.39 million shs1.12 million shsCRMDCorMedix$8.74-2.5%$7.81$6.13▼$17.43$702.93M1.461.30 million shs968,765 shsDRUGBright Minds Biosciences$60.95-1.0%$81.58$23.17▼$123.75$599.21M-5.53397,187 shs658,916 shsEQEquillium$2.81$2.27$0.27▼$3.45$177.67M1.771.14 million shs441,284 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+4.35%+0.44%-31.44%-13.48%+190.23%CRMDCorMedix+2.17%+4.92%+19.31%+38.91%-38.59%DRUGBright Minds Biosciences+0.02%-17.87%-27.27%-14.49%+121.87%EQEquillium+6.03%-10.69%+24.71%+14.62%+633.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 2.85Moderate Buy$46.67218.22% UpsideCRMDCorMedix 2.75Moderate Buy$15.0070.94% UpsideDRUGBright Minds Biosciences 2.86Moderate Buy$143.83134.30% UpsideEQEquillium 2.78Moderate Buy$7.57168.49% UpsideCurrent Analyst Ratings BreakdownLatest EQ, CRMD, AVTX, and DRUG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026AVTXAvalo Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/1/2026DRUGBright Minds Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$145.005/28/2026EQEquillium Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$7.005/28/2026EQEquillium Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$5.005/28/2026EQEquillium Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/28/2026EQEquillium Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$1.00 ➝ $6.005/26/2026AVTXAvalo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/20/2026DRUGBright Minds Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$190.00 ➝ $220.005/15/2026CRMDCorMedix Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/14/2026CRMDCorMedix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/14/2026AVTXAvalo Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$62.00 ➝ $55.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$59K13,065.77N/AN/A$4.49 per share3.27CRMDCorMedix$400.05M1.72$2.05 per share4.29$5.14 per share1.71DRUGBright Minds BiosciencesN/AN/AN/AN/A$8.33 per shareN/AEQEquillium$41.10M4.34N/AN/A$0.47 per share6.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$78.26M-$5.46N/AN/AN/AN/A-97.54%-72.42%8/6/2026 (Estimated)CRMDCorMedix$163.05M$2.134.1348.75N/A45.25%45.57%24.76%8/6/2026 (Estimated)DRUGBright Minds Biosciences-$8.74M-$2.44N/AN/AN/AN/A-20.58%-20.25%8/13/2026 (Estimated)EQEquillium-$22.40M-$0.32N/AN/AN/AN/A-61.43%-53.72%8/13/2026 (Estimated)Latest EQ, CRMD, AVTX, and DRUG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q2 2026DRUGBright Minds Biosciences-$0.8633-$0.80+$0.0633-$0.80N/AN/A5/14/2026Q1 2026CRMDCorMedix$0.35$0.43+$0.08$0.43$104.96 million$127.43 million5/13/2026Q1 2026AVTXAvalo Therapeutics-$1.00-$0.98+$0.02-$0.98$0.05 millionN/A5/13/2026Q1 2026EQEquillium-$0.04-$0.06-$0.02-$0.06N/AN/A3/25/2026Q4 2025EQEquillium-$0.07-$0.04+$0.03-$0.04N/AN/A3/23/2026Q4 2025AVTXAvalo Therapeutics-$1.54-$0.37+$1.17-$0.37($0.21) million$0.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A7.667.66CRMDCorMedix0.332.972.74DRUGBright Minds BiosciencesN/A81.4781.47EQEquilliumN/A18.6218.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%CRMDCorMedix34.18%DRUGBright Minds Biosciences40.52%EQEquillium27.05%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics4.46%CRMDCorMedix3.50%DRUGBright Minds Biosciences42.66%EQEquillium17.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4052.57 million50.22 millionNot OptionableCRMDCorMedix3078.45 million75.71 millionOptionableDRUGBright Minds BiosciencesN/A9.73 million5.58 millionNot OptionableEQEquillium4063.23 million51.95 millionNot OptionableEQ, CRMD, AVTX, and DRUG HeadlinesRecent News About These CompaniesAnalysts Grow More Confident In Equillium’s (EQ) Lead Asset EQ504June 10 at 3:11 PM | insidermonkey.comEquillium (NASDAQ:EQ) Insider Sells $632,000.00 in StockJune 8, 2026 | americanbankingnews.comEquillium (NASDAQ:EQ) COO Christine Zedelmayer Sells 14,584 SharesJune 6, 2026 | insidertrades.comRoth MKM Sticks to Its Buy Rating for Equillium (EQ)June 4, 2026 | theglobeandmail.comEquillium (EQ) Receives a Buy from B. Riley SecuritiesJune 4, 2026 | theglobeandmail.comEquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2026 | globenewswire.comEquillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease TranscriptJune 1, 2026 | seekingalpha.comInsider Selling: Equillium (NASDAQ:EQ) Insider Sells $191,750.00 in StockJune 1, 2026 | americanbankingnews.comInsider Selling: Equillium (NASDAQ:EQ) COO Sells $26,516.70 in StockJune 1, 2026 | americanbankingnews.comInsider Selling: Equillium (NASDAQ:EQ) COO Sells $240,833.60 in StockJune 1, 2026 | americanbankingnews.comEquillium (NASDAQ:EQ) COO Christine Zedelmayer Sells 9,821 SharesMay 30, 2026 | insidertrades.comChristine Zedelmayer Sells 9,821 Shares of Equillium (NASDAQ:EQ) StockMay 29, 2026 | marketbeat.comPenny Tom Sells 65,000 Shares of Equillium (NASDAQ:EQ) StockMay 29, 2026 | marketbeat.comChristine Zedelmayer Sells 86,012 Shares of Equillium (NASDAQ:EQ) StockMay 29, 2026 | marketbeat.comEquillium Shareholders Approve Reverse Split and Capital ChangesMay 29, 2026 | tipranks.comEquillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1May 29, 2026 | marketbeat.comEquillium to Participate in the 2026 Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comEquillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac DiseaseMay 27, 2026 | stockhouse.comEquillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 AxisMay 20, 2026 | globenewswire.comEquillium, Inc.: Equillium Reports First Quarter 2026 Financial Results and Corporate HighlightsMay 14, 2026 | finanznachrichten.deEquillium Reports First Quarter 2026 Financial Results and Corporate HighlightsMay 13, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesFrom High-Yield to High-Growth: 3 Stocks Boosting DividendsBy Leo Miller | May 18, 2026Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIABy Jeffrey Neal Johnson | May 21, 2026The SpaceX IPO Frenzy Is Creating 2 Very Different BetsBy Jeffrey Neal Johnson | May 27, 2026A Deep Dive Into NVIDIA’s Latest Portfolio MovesBy Leo Miller | May 19, 2026Amazon vs. Alibaba: One Is Clearly The Better Value Play right NowBy Sam Quirke | May 14, 2026EQ, CRMD, AVTX, and DRUG Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$14.76 +1.09 (+7.97%) Closing price 04:00 PM EasternExtended Trading$15.01 +0.25 (+1.69%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.CorMedix NASDAQ:CRMD$8.74 -0.22 (-2.46%) Closing price 04:00 PM EasternExtended Trading$8.86 +0.12 (+1.32%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Bright Minds Biosciences NASDAQ:DRUG$60.95 -0.62 (-1.01%) Closing price 04:00 PM EasternExtended Trading$60.63 -0.32 (-0.53%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Equillium NASDAQ:EQ$2.81 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.72 -0.09 (-3.02%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
